Skip Ribbon Commands
Skip to main content

About the CAVD

A preventative HIV vaccine has the potential to control the global AIDS epidemic and avert the suffering of millions of people. Roughly 6,000 people become infected with HIV each day, for a total of approximately 2.7 million new infections per year. Worldwide, an estimated 33 million people are living with HIV/AIDS, with 22 million of those individuals living in sub-Saharan Africa.

Despite over 20 years of HIV vaccine research, the scientific challenges have so far blocked the development of a preventative vaccine. As a result, HIV vaccine scientists, advocates, and funders are searching for innovative approaches to vaccine research and development. One such approach emphasizes collaboration and concentration of effort by a worldwide network of researchers dedicated to accelerating the pace of HIV vaccine research.

The CAVD provides funding for a range of innovative strategies aimed at designing an effective HIV vaccine. The program is designed to foster collaboration among researchers to speed up the communication of results and the sharing of ideas. In addition to focusing on fundamental HIV research, the funded projects emphasize translational research, bridging the gap between basic discovery and product development.

The CAVD approach is based on the principle that HIV vaccine development will progress most rapidly and has the highest chance of success if the individual initiatives are complemented by a collaborative effort. Small teams of independent researchers conduct much of today’s scientific work, and their findings form the basis for numerous innovations. However, independent efforts have thus far failed to produce a preventative vaccine, and a consensus has emerged among researchers, advocates, and funders that large-scale projects featuring collaboration and concentration of efforts could accelerate the pace of HIV vaccine research.

The CAVD fosters a spirit of open communication and sharing not only of data but also of methods, reagents, and specimens in a collegial network of research consortia and central service facilities.

The program seeks a balance between productive competition and collaboration. The grantees use standardized tools and common preclinical and clinical platforms that permit the evaluation and sharing of results, while preserving the independent research crucial to innovation.

See About the CAVD Structure…

Former CAVD Collaborators/Consortia

  
  
Shattock: Novel Antigens for Mucosal Protection2005
​Ho: Enhancing Innate Immune Activation2006
Greenberg: Mouse Immunology Laboratory2006
Haynes: Broad Neutralizing Antibody Consortium2006
Lehner Vaccine Discovery Consortium2006
Letvin: rAdenoviral & rMycobacterial Vector Immunogens2006
McElrath: Innate to Adaptive Immunity2006
Parks: Replicating Viral Vaccine Vectors2006
Patterson: CD8 Broadening Strategies2006
Plummer, Grand Challenges in Global Health2006
​Reinherz: HIV clade C MPER immunogens eliciting 10E8-like speci cities2006
Stamatatos: Novel HIV Immunogen Vaccines2006
Weiss: Protection by Neutralizing Antibodies2006
Zolla-Pazner: Epitope-Scaffold Immunogens2006
​Gallo: Systemic, Mucosal & Passive Immunity2007
Walker: HIV Control & Immunogen Design2007
Ho: Ibalizumab for HIV Prevention2009
von Briesen: HIV Specimen Cryorepository2009
Wilson: Vector-Mediated Passive Immunization2009
​Frank: Studies to Maximize Immunogenicity2011
​Picker: Development of Attenuated CMV Vectors for an HIV/AIDS Vaccine2011
Barouch: Replicating Adenovirus Vectors2011
Haynes: B-Cell Lineage Envelope Design2011
Hope: Antibody-Mucus Interactions2011
​Hu: Unmasking Conserved Epitopes2011
Lu: Creating Novel Envelope Immunogens with Unique Sugar Coats for HIV Vaccine Development2011
Mascola: BNAbs for Passive Immunization2011
​Nussenzweig: Isolation of Human Monoclonal Antibodies for HIV Prevention​2011
​Parks: HIV Vaccine Clinical Candidates based on Replication-Competent Viral Vectors that Preferentially Replicate in Lymphoid Tissues2011
Schmitz/Santra: Second Generation rBCG Immunogens2011
​​Haynes: Role of IgA in HIV-1 Protection2012
​​Ho: Engineered Bispecific bNAbs for Prevention2012
​Bjorkman: Improving Potency and Breadth of Natural bNAbs2012
Barouch: Novel Vector/Protein Vaccines2012
​Pantaleo: RepliVax Vaccine Platform2012
Walker: bNAbs after Infection and Immunization2012
Kay: Identifying rAAV Vectors with Enhanced Muscle Transduction via Capsid Evolution2013
Kublin: HIV Vaccine Trials Site Development for the P5 Program2013
​​​McElrath: Mucosal Immunology Group2013
Silvestri: Independent Confirmation of Inactivated AT-2 Treated SIV mac239 and Lactobacillus2013
​Nolan: Technology Development for HIV Reservoir Characterization2014
​Pantaleo: Generation/Isolation of Novel bNAbs from Lymph Node B cells2014
​Ruprecht: Confirming the Efficacy of Virosomes Targeting gp41 in Indian Rhesus Macaques2014
​Deeks: Experimental medicine trial to assess the impact of interferon-alpha inhibition on immune function and viral persistence in HIV disease2014
Kay: Comparative NHP Study to Test New Capside Against AAV12016
Parks: HIV Vaccine Clinical Candidates based on Replication-Competent Viral Vectors that Preferentially Replicate in Lymphoid Tissues2016
Parks: Live Attenuated VSV-HIV-Env Vaccine Candidate for Evaluation in a Clinical Trial (I)2016
Parks: Live Attenuated VSV-HIV-Env Vaccine Candidate for Evaluation in a Clinical Trial (II)2016
Shaw: Novel SHIV Design to Elicit Broadly Neutralizing Antibodies and Guide Iterative Vaccine Development2016
 
 
For general questions about the CAVD or the content of the these pages, please contact alliance.management@cavd.org.
For technical issues with the website, please contact portalsupport@cavd.org.